Christopher U. Meduri

Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli

Ole De Backer, Arif Azhar Khokhar, Gintautas Bieliauskas, Azeem Latib et autres

BACKGROUND: Transcatheter aortic valve implantation (TAVI) in patients with small aortic annuli (SAA) is associated with an increased risk of prosthesis-patient mismatch (PPM). AIMS: This study assesses the 30-day performance of the novel balloon-expandable DurAVR transcatheter heart valve (THV), which features a …

de, dk, us, se, fr, ch, cz (code pays fourni par la source)

Durability of No-Implant Interatrial Shunt for HFpEF

Brian James Potter, Colin M. Barker, GERARD T. WILKINS, Benjamin J. Wilkins et autres

ca, us, nz, au, se (code pays fourni par la source)

Mitral Annular Function in Mitral Annular Calcification and Severe Mitral Regurgitation

Joseph T. Kassab, Joseph Hajj, Serge C. Harb, Rhonda Miyasaka et autres

BACKGROUND: Longitudinal left ventricular (LV) shortening, or mitral atrioventricular plane displacement (AVPD), reflects mitral annular function. OBJECTIVES: The authors sought to demonstrate the use of cardiac computed tomography (CCT) to measure mitral AVPD and assess its contribution to LV stroke volume (LVSV) …

us, se (code pays fourni par la source)

DurAVR – a novel biomimetic balloon-expandable transcatheter valve for TAVI, valve-in-valve TAVI and redo-TAVI

David Meier, Althea Lai, Rebecca Tung Hahn, João L. Cavalcante et autres

BACKGROUND: The DurAVR transcatheter heart valve (THV) is a novel biomimetic balloon-expandable valve with promising early clinical results. AIMS: We aimed to assess the hydrodynamic performance of the DurAVR THV in native, valve-in-valve (ViV), and redo-transcatheter aortic valve implantation (TAVI) procedures against …

ch, ca, us, gb, se (code pays fourni par la source)

The importance of tissue science and valve design in relation to durability and hemodynamics of the DurAVR aortic heart valve

William M. L. Neethling, Guenther Forster, Christopher U. Meduri, Bart Meuris et autres

Introduction: Clinical evidence highlighting the efficacy and safety of transcatheter aortic valve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heart valve (BHV) leaflet …

au, se, be, ca, us (code pays fourni par la source)

TCT-468 No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: 12-Month Outcomes From Multicenter Pilot Feasibility Studies

Brian James Potter, James E. Udelson, Colin Barker, Ben Wilkins et autres

ca, us, nz, au, se, ge (code pays fourni par la source)

Midterm durability of the ACURATE transcatheter aortic valve implantation system based on VARC-3 definitions

Andreas Rück, Bahira Shahim, Aristomenis Manouras, Christopher U. Meduri et autres

se, ie (code pays fourni par la source)

E-25 | DurAVR biomimetic transcatheter heart valve: Early Feasibility Study update

Christopher U. Meduri, Azeem Latib, Susheel Kodali, Gorav Ailawadi et autres

The Anteris DurAVR transcatheter heart valve (THV) system (Anteris Technologies, Minneapolis, USA) is a first-in-class biomimetic THV with differentiating design features: single-piece leaflet geometry for optimal hemodynamics and flow characteristics; ADAPT anti-calcification process to reduce bioprosthetic SVD; intra-annular balloon-expandable platform with large …

se, us (code pays fourni par la source)

LB-10 | Update from the First-in-human Study with the Novel DurAVR Biomimetic Transcatheter Heart Valve

Christopher U. Meduri, Susheel Kodali, Azeem Latib, Rishi Puri et autres

The Anteris DurAVR transcatheter heart valve (THV) system (Anteris Technologies, Minneapolis, USA) is a first-in-class biomimetic THV with differentiating design features: single-piece leaflet geometry for optimal hemodynamics and flow characteristics; ADAPT anti-calcification process to reduce SVD; balloon-expandable platform with large open-cell geometry …

se, us, gb (code pays fourni par la source)

OR13-2 | No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly-Reduced Ejection Fraction: Twelve-Month Outcomes from Multi-Center ALLEVIATE Feasibility Studies

Binita Shah, James E. Udelson, Colin M. Barker, GERARD T. WILKINS et autres

Interatrial shunt procedures currently under clinical evaluation to treat refractory heart failure require a permanent device implant to maintain patency. The Alleviant device percutaneously excises interatrial septal tissue using a pulse of RF energy and does not require a permanent implant to …

us, au, nz, ca, se (code pays fourni par la source)

OR7-3 | DurAVR biomimetic transcatheter heart valve: first-in-human study results update

Christopher U. Meduri, Susheel Kodali, Azeem Latib, Rishi Puri et autres

The Anteris DurAVR transcatheter heart valve (THV) system (Anteris Technologies, Minneapolis, USA) is a first-in-class biomimetic THV with differentiating design features: single-piece leaflet geometry for optimal hemodynamics and flow characteristics; ADAPT anti-calcification process to reduce bioprosthetic SVD; balloon-expandable platform with large open-cell …

se, us, gb (code pays fourni par la source)

NO-IMPLANT INTERATRIAL SHUNT FOR HEART FAILURE WITH PRESERVED AND MILDLY-REDUCED EJECTION FRACTION: TWELVE-MONTH OUTCOMES FROM MULTI-CENTER PILOT FEASIBILITY STUDIES

James E. Udelson, Colin M. Barker, GERARD T. WILKINS, Ben Wilkins et autres

us (code pays fourni par la source)